Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER,...
Melanoma
Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients 47% ORR, 5.5 months mPFS observed with preferred...
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a...
Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology
The companies are executing on the shared vision of utilizing AI for effective knowledge management in the pharmaceutical research and...
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation...
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosisFirst time efti...
Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 GP-2250’s antineoplastic effects on ovarian cancer cells...
$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology
Providence, RI, April 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (“Ocean”), a biopharma company working to accelerate the development...
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T...
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing...
HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19
TUCSON, Ariz., April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools...
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Vaccinex Announces Private Placement with Commitments of $5.0 Million
ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated...
Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update
NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study
- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts...
Press release Biocartis Group NV: Biocartis To Publish 2022 Annual Report on 11 April 2023
PRESS RELEASE - REGULATED INFORMATION 29 March 2023, 07:00 CEST Biocartis To Publish 2022 Annual Report on 11 April 2023...
Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy
Proprietary bi-functional ADCs target and inhibit unique Delta receptor on tumor-associated Myeloid Derived Suppressor Cells (MDSCs); increasing tumor’s susceptibility to...
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission to U.S. Food and Drug AdministrationSAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance...
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured...